A Phase II Trial of CG 8020 and CG 2505 in Patients With Nonresectable or Metastatic Pancreatic Cancer
Metastatic Pancreatic Cancer, Nonresectable Pancreatic Cancer
About this trial
This is an interventional treatment trial for Metastatic Pancreatic Cancer focused on measuring cancer vaccine, pancreatic cancer, metastatic pancreatic cancer, unresectable pancreatic cancer, immunotherapy
Eligibility Criteria
Inclusion Criteria: Histologic or cytologic diagnosis of nonresectable or metastatic pancreatic adenocarcinoma Chemotherapy naïve or chemotherapy experienced pancreatic cancer Exclusion Criteria: Prior cancer vaccines or gene therapy History of clinically significant autoimmune disease (eg, systemic lupus erythematosus, sarcoidosis, rheumatoid arthritis, glomerulonephritis, or vasculitis) History of another malignancy in the past five years, except adequately treated non-melanomatous skin cancer or superficial bladder cancer or carcinoma-in-situ of the cervix, unless approved by the Medical Monitor
Sites / Locations
- Johns Hopkins University School of Medicine
- US Oncology